Company: APXIF
Filing Date: 2025-01-22
Form Type: F-4
Source: 0001213900-25-005463
Chunk: 241

Company: APx Acquisition Corp. I
Filing Date: 2025-01-22
Form: F-4
Chunk 241
---
 | % |     |            |     12.21 | % |
| Transaction costs reflected in Share premium (in millions)                |     | $          |      0.46 |   |     | $          |      0.43 |   |     | $          |      0.41 |   |
| Transaction costs reflected in Statement of Operations (in millions)      |     | $          |      2.87 |   |     | $          |      2.90 |   |     | $          |      2.92 |   |

____________ Notes:- (i)As of June 30, 2024, the number of shares to be issued form APx shareholders was 4,832,556 (4,312,500 corresponding to Initial Shareholders and 520,056 corresponding to Public Shareholders). The number of shares corresponding to the Public Shareholders includes the effects of redemptions after June 30, 2024, described in Note (1) under “ Adjustments to Unaudited Pro Forma Combined Consolidated Statement of Financial Position as of June 30, 2024.” (2)Represents the amortization of acquired intangible assets. See footnote (8) under “ Adjustments to Unaudited Pro Forma Combined Consolidated Statement of Financial Position as of June 30, 2024” section for details. (3)Represents the preliminary estimated expense recognized, in accordance with IFRS 2, for the excess of the fair value of the Company Shares issued over the book value of APx identifiable net assets at the date of the Business Combination (including the recognition of APx transaction costs, as described in Note (1) under “ Adjustments to Unaudited Pro Forma Combined Consolidated Statement of Operations for the Year Ended June 30, 2024.” See footnote (5) under “ Adjustments to Unaudited Pro Forma Combined Consolidated Statement of Financial Position as of June 30, 2024” section. (4)To reflect the elimination of (a) interest income on marketable securities held in the Trust Account of APx and (b) the financial cost due to the change in the fair value of common shares of APx, subject to possible redemptions. (5)Represents the interest expense corresponding to intercompany loans agreements with OmnigenicsAI’s parent companies. See footnote (6) under “ Adjustments to Unaudited Pro Forma Combined Statement